Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-stage Phase 2A and 2B clinical study to determine the safety and efficacy of CX1739 to improve bladder function and motor activity in individuals with spinal cord injury (SCI)

Next Previous
Trial Profile

A 2-stage Phase 2A and 2B clinical study to determine the safety and efficacy of CX1739 to improve bladder function and motor activity in individuals with spinal cord injury (SCI)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 31 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CX 1739 (Primary)
  • Indications Spinal cord injuries
  • Focus Therapeutic Use

Most Recent Events

  • 29 May 2024 According to a RespireRx Pharmaceuticals media release, company announced that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study.
  • 25 Mar 2024 New trial record
  • 20 Mar 2024 According to a RespireRx Pharmaceuticals Inc, study is planned to begin late in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top